Strategy+ advised one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare disease. The definitive agreement was announced May 8, 2019. Pfizer agreed to $340 Million upfront with $470 Million contingent on the achievement of key milestones.